Orion Portfolio Solutions LLC Sells 8,634 Shares of DexCom, Inc. (NASDAQ:DXCM)

Orion Portfolio Solutions LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 70.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,557 shares of the medical device company's stock after selling 8,634 shares during the quarter. Orion Portfolio Solutions LLC's holdings in DexCom were worth $238,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom during the second quarter worth $25,000. Sachetta LLC raised its stake in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom during the third quarter worth about $57,000. Finally, Covestor Ltd grew its holdings in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after buying an additional 335 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Price Performance

NASDAQ DXCM traded up $4.22 during trading on Friday, hitting $80.04. 11,494,120 shares of the company's stock were exchanged, compared to its average volume of 3,910,878. The stock's 50 day moving average price is $74.53 and its two-hundred day moving average price is $83.10. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market cap of $31.26 billion, a PE ratio of 47.93, a P/E/G ratio of 2.46 and a beta of 1.12.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on DXCM shares. Citigroup boosted their target price on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. Leerink Partners decreased their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Finally, Canaccord Genuity Group raised their price objective on DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a report on Monday, December 9th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.